Companies › Atavistik Bio
1 active drug program in 2 registered trials: 2 Phase 1; Hematology, Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ATV-1601 AKT1 E17K inhibitor | AKT1 | Phase 1 | Hereditary Hemorrhagic Telangiectasia (HHT); Advanced Solid Tumors | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07601425 | ATV-1601 | Phase 1 | Hereditary Hemorrhagic Telangiectasia (HHT) | Hematology | Dec 2027 |
| NCT07038369 | ATV-1601 | Phase 1 | Advanced Solid Tumors | Oncology | Aug 2028 |
AstraZeneca Merck & Co. (MSD) Roche Laekna Alterome Therapeutics Zhejiang Haichang Biotech
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.